[1]
Turnšek, N., Devjak, R., Edelbaher, N., Osrajnik, I., Unk, M., Vidovič, D., Jerič, T. and Janžič, U. 2022. Real-world outcomes, treatment patterns and T790M testing rates in Non-Small Cell Lung Cancer patients treated with first-line first- or second-generation epidermal growth factor receptor tyrosine kinase inhibitors from the Slovenian cohort of the REFLECT: Outcomes and treatments of EGFR-mutated NSCLC patients from Slovenia. Radiology and Oncology. 56, 3 (Sep. 2022), 371–379.